News Releases

News Releases

Sep 10, 2020
PRINCETON, N.J. --(BUSINESS WIRE)--Sep. 10, 2020-- UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options, today announced that it will present at the following
Aug 27, 2020
Trial Did Not Meet Primary Endpoint Believed to be the Result of BOTOX Not Effectively Permeating the Urothelium RTGel Delivered Treatment to the Bladder as Expected with Dwell Time of Up to 10 Hours UroGen and AbbVie will Continue to Explore Use of the RTGel Hydrogel Formulation with AbbVie’s
Jun 01, 2020
PRINCETON, N.J. --(BUSINESS WIRE)--Jun. 1, 2020-- UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that Liz Barrett , President and Chief Executive Officer,